| Literature DB >> 29556347 |
Zhuang Liu1, Han Lin2,3, Menglong Zhao4, Chen Dai5, Shengjian Zhang1, Weijun Peng1, Yu Chen2.
Abstract
Background: The emergence of two-dimensional al">MXenes has spurred their versatile applications in broad fields, but the exploring of novel <span class="Chemical">MXene-based family members and their potential applications in theranostic nanomedicine (concurrent diagnostic imaging and therapy) have been rarely explored. In this work, we report the construction of a novel superparamagnetic MXene-based theranostic nanoplatform for efficient breast-cancer theranostics, which was based on intriguing tantalum carbide (Ta4C3) MXene and its further rational surface-superparamagnetic iron-oxide functionalization (Ta4C3-IONP-SPs composite MXenes) for efficient breast-cancer theranostic.Entities:
Keywords: Fe3O4; MXene; Multimodal imaging; Nanomedicine; Photothermal therapy; Tantalum carbide
Mesh:
Substances:
Year: 2018 PMID: 29556347 PMCID: PMC5858173 DOI: 10.7150/thno.23369
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 4(A) Photothermal-responding profiles of Ta4C3-IONP-SPs under laser irradiation (808 nm, 1.5 W cm-2) for 10 min at elevated concentrations, and (B) the corresponding infrared thermal images. (C) Heating/cooling profiles of Ta4C3-IONP-SPs dispersed in deionized water (200 ppm) for four cycles of laser irradiation (808 nm, 1.5 W cm-2). (D) Temperature-changing profile of Ta4C3-IONP-SPs (200 ppm) under 808 nm laser at 1.5 W cm-2 until reaching the temperature-steady state. (E) UV-vis spectra of Ta4C3-IONP-SPs at various concentrations (12.5, 25, 50, 100, 200 ppm). Inset: normalized absorbance intensity at λ = 808 nm. (F) 3D-schematic illustration of Ta4C3-IONP-SPs as PTAs for 4T1 cell ablation under the exposure to 808 nm laser irradiation. (G) Relative viabilities of 4T1 cells after incubation with Ta4C3-IONP-SPs at elevated concentrations for 24 h. (H) Relative viabilities of 4T1 cells after incubation with Ta4C3-IONP-SPs with or without laser irradiation (808 nm, 1.5 W cm-2, 10 min). **significant difference at P ˂ 0.01. (I) Confocal fluorescence images of calcein AM (green, live cells) and propidium iodide (red, cells) co-stained cells after the incubation with Ta4C3-IONP-SPs under different treatments.
Figure 1Schematic illustration of the fabrication process of Ta4C3-IONP-SPs composite nanosheets and their unique functionality for dual-modal contrast-enhanced MRI/CT imaging-guided photothermal ablation of breast cancer.
Figure 2(A, B) TEM, (C) HRTEM and (D) SAED pattern images of as-synthesized 2D ultrathin Ta4C3 nanosheets. (E, F) TEM, (G) HRTEM and (H) SAED pattern images of multi-functionalized Ta4C3-IONP composite nanosheets. (I) X-ray diffraction (XRD) profiles of Ta4C3 nanosheets and Ta4C3-IONP composite MXenes. (J) EDS and (K, L) EELS of Ta4C3-IONP composite MXenes.
Figure 3(A) STEM images of Ta4C3-IONP composite MXenes and corresponding element mapping images, showing the uniform distribution of Ta (purple) and Fe (yellow) elements in the whole matrix. (B) FTIR spectra of as-synthesized Ta4C3 nanosheets and Ta4C3-IONP composite nanosheets. XPS spectra of (C) Ta4C3 nanosheets and (D) Ta4C3-IONP composite nanosheets. Corresponding XPS spectra of (E) Fe 2p and (F) O 1s peaks of Ta4C3-IONP composite MXenes. (G) Magnetization curves of Ta4C3-IONP composite MXenes (Inset: a typical photographic image showing the facile magnetic separation of Ta4C3-IONP composite MXenes by an outer applied magnet). (H) Photographs of Ta4C3-IONP and Ta4C3-IONP-SPs composite nanosheets dispersed in various solutions (water, DMEM, PBS, saline and SBF).
Figure 5(A) In vitro T2-weighted MR imaging and T2 relaxivity of Ta4C3-IONP-SPs composite MXenes. (B) Transverse and coronal section of T2-weighted MR imaging of 4T1 tumor-bearing mouse before and after intravenous injection of Ta4C3-IONP-SPs at given time points, and (C) the corresponding T2-weighted MRI signal intensities of tumor site at varied time points after the intravenous administration of Ta4C3-IONP-SPs composite MXenes. The tumor sites were marked by red arrows and yellow circles.
Figure 6In vitro (A) CT images and (B) the corresponding CT values (HU) of Ta4C3-IONP-SPs composite MXenes and iopromide solutions at varied concentrations. (C) Transverse, coronal and 3D-rendering CT images of 4T1 tumor-bearing mouse before and after intravenous injection of Ta4C3-IONP-SPs, and (D) time-dependent corresponding CT values of tumor site after the intravenous administration of Ta4C3-IONP-SPs composite MXenes. The tumor sites were marked by red circles.
Figure 7(A) In vivo IR images of 4T1 tumor-bearing mice before and after intravenous injection of Ta4C3-IONP-SPs MXenes under the exposure to laser irradiation (808 nm, 1.5 W cm-2, 10 min), and (B) the corresponding temperature elevation of tumor sites during the period of laser irradiation. (C) Time-dependent body-weight changing profiles and (D) tumor-volume changing curves of four groups of 4T1 tumor-bearing mice after different treatments. *significant difference at P ˂ 0.05. **significant difference at P ˂ 0.01. (E) Photographs of 4T1 tumor-bearing mice at the 14th day after various treatments, (F) corresponding photographs, and (G) tumor weight of 4T1 tumors collected from all groups after varied treatments. (H) Antigen Ki-67 immunofluorescence, Tunel and H&E stained histological sections of tumor tissues from the mice after PTT treatment in each group (scale bar, 100 µm).
Figure 8(A-L) Hematological test of Kunming mice from the control group and three treatment groups at 30th days after intravenous injection of Ta4C3-IONP-SPs at elevated doses (0, 5, 10 and 20 mg kg-1). (M) H&E staining tissue sections of main organs including heart, liver, spleen, lung and kidney of Kunming mice after single intravenous injection of Ta4C3-IONP-SPs (0, 5, 10 and 20 mg kg-1) for 30 days feeding. All the scale bars are 100 μm.